THE Therapeutic Goods Administration (TGA) has warned against importing unregistered GLP-1 products being promoted for weight loss.
"The products are often marketed as 'GLP-1 peptide' oral drops or liquids and may be falsely labelled as approved by international regulators or advertised with misleading quality marks or claims with the aim of deliberately deceiving consumers," the regulator explained.
"We are also aware of reports of advertising containing fake health professional and celebrity endorsements for these products," they added.
The TGA has asked health professionals to advise patients of the risks associated with unregistered GLP-1 products, and to report adverse events involving medicines, including unapproved medicines.
This can help the TGA in identifying previously unknown side effects and other safety issues.
The TGA has also issued 10 infringement notices, totalling $198,000, to Midnight Health for the alleged unlawful advertising of prescription-only weight-loss medicines, which the company has paid.
The company operated telehealth platforms such as Youly, Stagger and hub.health, where it advertised prescription-only weight-loss medicines, including tirzepatide and semaglutide, to the public between Jun 2024 and Jan 2025.
Learn more HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 30 Sep 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 30 Sep 25
